NYSE:MRK - Merck & Co. Stock Price, Price Target & More

$58.64 -0.28 (-0.48 %)
(As of 04/20/2018 05:12 AM ET)
Previous Close$58.92
Today's Range$58.42 - $59.32
52-Week Range$52.83 - $66.41
Volume10.54 million shs
Average Volume13.12 million shs
Market Capitalization$159.80 billion
P/E Ratio14.73
Dividend Yield3.24%
Beta0.78

About Merck & Co. (NYSE:MRK)

Merck & Co. logoMerck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., and IO Biotech. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:MRK
CUSIP58933Y10
Phone908-740-4000

Debt

Debt-to-Equity Ratio0.62%
Current Ratio1.33%
Quick Ratio1.06%

Price-To-Earnings

Trailing P/E Ratio14.73
Forward P/E Ratio14.10
P/E Growth2.48

Sales & Book Value

Annual Sales$40.12 billion
Price / Sales3.94
Cash Flow$5.6548 per share
Price / Cash10.37
Book Value$12.69 per share
Price / Book4.62

Profitability

EPS (Most Recent Fiscal Year)$3.98
Net Income$2.39 billion
Net Margins6.40%
Return on Equity28.61%
Return on Assets11.85%

Miscellaneous

Employees69,000
Outstanding Shares2,696,190,000

How to Become a New Pot Stock Millionaire

Merck & Co. (NYSE:MRK) Frequently Asked Questions

What is Merck & Co.'s stock symbol?

Merck & Co. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Co. pay dividends? What is the dividend yield for Merck & Co.?

Merck & Co. declared a quarterly dividend on Tuesday, January 23rd. Stockholders of record on Thursday, March 15th will be given a dividend of $0.48 per share on Friday, April 6th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.27%. The ex-dividend date of this dividend is Wednesday, March 14th. View Merck & Co.'s Dividend History.

How will Merck & Co.'s stock buyback program work?

Merck & Co. announced that its board has approved a share buyback plan on Saturday, December 2nd 2017, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its stock is undervalued.

How were Merck & Co.'s earnings last quarter?

Merck & Co. (NYSE:MRK) released its quarterly earnings results on Friday, February, 2nd. The company reported $0.98 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.94 by $0.04. The business had revenue of $10.43 billion for the quarter, compared to the consensus estimate of $10.48 billion. Merck & Co. had a return on equity of 28.61% and a net margin of 6.40%. The company's revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.89 EPS. View Merck & Co.'s Earnings History.

When is Merck & Co.'s next earnings date?

Merck & Co. is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Merck & Co..

What guidance has Merck & Co. issued on next quarter's earnings?

Merck & Co. issued an update on its FY18 earnings guidance on Friday, February, 2nd. The company provided earnings per share guidance of $4.08-4.23 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.11. The company issued revenue guidance of $41.2-42.7 billion, compared to the consensus revenue estimate of $41.10 billion.

What price target have analysts set for MRK?

18 Wall Street analysts have issued 1-year price objectives for Merck & Co.'s shares. Their predictions range from $56.00 to $74.00. On average, they anticipate Merck & Co.'s stock price to reach $66.6875 in the next twelve months. View Analyst Ratings for Merck & Co..

Who are some of Merck & Co.'s key competitors?

Who are Merck & Co.'s key executives?

Merck & Co.'s management team includes the folowing people:
  • Mr. Kenneth C. Frazier, Chairman, CEO & Pres (Age 63)
  • Mr. Robert M. Davis, CFO & Exec. VP of Global Services (Age 51)
  • Mr. Michael J. Holston, Exec. VP & Gen. Counsel (Age 56)
  • Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 66)
  • Mr. Adam H. Schechter, Exec. VP & Pres of Global Human Health (Age 53)

Has Merck & Co. been receiving favorable news coverage?

News stories about MRK stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Merck & Co. earned a coverage optimism score of 0.24 on Accern's scale. They also assigned news coverage about the company an impact score of 46.98 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Merck & Co.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merck & Co.'s stock price today?

One share of MRK stock can currently be purchased for approximately $58.64.

How big of a company is Merck & Co.?

Merck & Co. has a market capitalization of $159.80 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co. employs 69,000 workers across the globe.

How can I contact Merck & Co.?

Merck & Co.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]


MarketBeat Community Rating for Merck & Co. (MRK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  606 (Vote Outperform)
Underperform Votes:  620 (Vote Underperform)
Total Votes:  1,226
MarketBeat's community ratings are surveys of what our community members think about Merck & Co. and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Merck & Co. (NYSE:MRK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
18 Wall Street analysts have issued ratings and price targets for Merck & Co. in the last 12 months. Their average twelve-month price target is $66.6875, suggesting that the stock has a possible upside of 13.72%. The high price target for MRK is $74.00 and the low price target for MRK is $56.00. There are currently 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.722.612.532.56
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $66.6875$66.1875$66.8750$70.7692
Price Target Upside: 13.72% upside20.04% upside7.74% upside10.78% upside

Merck & Co. (NYSE:MRK) Consensus Price Target History

Price Target History for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE:MRK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018Bank of AmericaBoost Price TargetBuy -> Buy$68.00 -> $70.00LowView Rating Details
4/17/2018Morgan StanleyUpgradeEqual Weight -> Overweight$59.80 -> $63.00LowView Rating Details
4/16/2018BMO Capital MarketsReiterated RatingBuy$65.00HighView Rating Details
4/13/2018Jefferies GroupSet Price TargetHold$56.00LowView Rating Details
4/5/2018BarclaysUpgradeEqual Weight -> Overweight$62.00 -> $64.00LowView Rating Details
3/12/2018Leerink SwannUpgradeMarket Perform -> OutperformLowView Rating Details
2/14/2018Credit Suisse GroupLower Price TargetOutperform -> Outperform$66.00 -> $65.00LowView Rating Details
2/13/2018DZ BankUpgradeHold -> BuyLowView Rating Details
1/16/2018SunTrust BanksUpgradeHold -> Buy$54.00 -> $72.00HighView Rating Details
11/24/2017Deutsche BankLower Price TargetHold -> Hold$62.00 -> $59.00N/AView Rating Details
11/15/2017Sanford C. BernsteinReiterated RatingBuy$64.00N/AView Rating Details
11/3/2017CowenReiterated RatingHold$70.00N/AView Rating Details
11/1/2017Berenberg BankReiterated RatingHoldN/AView Rating Details
10/30/2017CitigroupUpgradeBuyN/AView Rating Details
10/30/2017UBSLower Price TargetBuy$72.00 -> $67.00N/AView Rating Details
10/29/2017JPMorgan ChaseSet Price TargetBuy$70.00N/AView Rating Details
7/29/2017Piper JaffraySet Price TargetBuy$70.00LowView Rating Details
7/27/2017Goldman SachsReiterated RatingNeutral$70.00 -> $74.00MediumView Rating Details
1/13/2017Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
1/12/2017GuggenheimUpgradeNeutral -> Buy$61.63 -> $70.00N/AView Rating Details
10/27/2016ArgusReiterated RatingBuy$65.00 -> $80.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Merck & Co. (NYSE:MRK) Earnings History and Estimates Chart

Earnings by Quarter for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE:MRK) Earnings Estimates

2018 EPS Consensus Estimate: $4.19
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.96$1.01$0.99
Q2 20182$1.04$1.11$1.08
Q3 20182$1.09$1.13$1.11
Q4 20182$0.97$1.06$1.02

Merck & Co. (NYSE MRK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018N/AView Earnings Details
2/2/2018Q4 2017$0.94$0.98$10.4850 billion$10.4330 billionViewListenView Earnings Details
10/27/2017Q3 2017$1.03$1.11$10.5450 billion$10.3250 billionViewN/AView Earnings Details
7/28/2017Q2 17$0.87$1.01$9.7463 billion$9.93 billionViewN/AView Earnings Details
5/2/2017Q1 2017$0.83$0.88$9.2539 billion$9.4340 billionViewListenView Earnings Details
2/2/2017Q416$0.8890$0.89$10.22 billion$10.10 billionViewListenView Earnings Details
10/25/2016Q316$0.99$1.07$10.17 billion$10.50 billionViewListenView Earnings Details
7/29/2016Q216$0.91$0.93$9.79 billion$9.84 billionViewListenView Earnings Details
5/5/2016Q116$0.85$0.89$9.45 billion$9.30 billionViewN/AView Earnings Details
2/3/2016Q415$0.91$0.93$10.32 billion$10.22 billionViewListenView Earnings Details
10/27/2015Q315$0.91$0.96$10.11 billion$10.10 billionViewListenView Earnings Details
7/28/2015Q215$0.80$0.86$9.81 billion$9.80 billionViewListenView Earnings Details
4/28/2015Q115$0.75$0.85$9.04 billion$9.40 billionViewListenView Earnings Details
2/4/2015Q414$0.85$0.87$10.61 billion$10.48 billionViewListenView Earnings Details
10/27/2014Q314$0.88$0.90$10.66 billion$10.56 billionViewListenView Earnings Details
7/29/2014Q214$0.81$0.85$10.60 billion$10.93 billionViewListenView Earnings Details
4/29/2014Q114$0.79$0.88$10.44 billion$10.30 billionViewListenView Earnings Details
2/5/2014Q413$0.88$0.88$11.39 billion$11.30 billionViewListenView Earnings Details
10/28/2013Q313$0.88$0.92$11.19 billion$11.03 billionViewListenView Earnings Details
7/30/2013Q2 2013$0.82$0.84$11.22 billion$11.01 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.79$0.85$11.09 million$10.70 millionViewListenView Earnings Details
2/1/2013Q4 2012$0.81$0.83$11.46 billion$11.70 billionViewListenView Earnings Details
10/26/2012Q312$0.92$0.95$11.60 billion$11.50 billionViewN/AView Earnings Details
7/27/2012$1.02$1.05ViewN/AView Earnings Details
4/27/2012$0.98$0.99ViewN/AView Earnings Details
2/2/2012$0.95$0.97ViewN/AView Earnings Details
10/28/2011$0.91$0.94ViewN/AView Earnings Details
7/29/2011$0.94$0.95ViewN/AView Earnings Details
4/29/2011$0.84$0.92ViewN/AView Earnings Details
2/3/2011$0.83$0.88ViewN/AView Earnings Details
10/29/2010Q3 2010$0.83$0.85ViewN/AView Earnings Details
7/30/2010Q2 2010$0.82$0.86ViewN/AView Earnings Details
5/4/2010Q1 2010$0.75$0.84ViewN/AView Earnings Details
2/16/2010Q4 2009$0.78$0.80ViewN/AView Earnings Details
10/22/2009Q3 2009$0.82$0.90ViewN/AView Earnings Details
7/21/2009Q2 2009$0.78$0.83ViewN/AView Earnings Details
4/21/2009Q1 2009$0.77$0.74ViewN/AView Earnings Details
2/3/2009Q4 2008$0.74$0.87ViewN/AView Earnings Details
10/22/2008Q3 2008$0.79$0.80ViewN/AView Earnings Details
7/21/2008Q2 2008$0.83$0.86ViewN/AView Earnings Details
4/21/2008Q1 2008$0.85$0.89ViewN/AView Earnings Details
1/30/2008Q4 2007$0.73$0.80ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Merck & Co. (NYSE:MRK) Dividend Information

Merck & Co. pays an annual dividend of $1.92 per share, with a dividend yield of 3.27%. MRK's most recent quarterly dividend payment was Friday, April 6. The company has grown its dividend for the last 6 consecutive years and is increasing its dividend by an average of 2.20% each year. Merck & Co. pays out 48.24% of its earnings out as a dividend.
Most Recent Dividend:4/6/2018
Annual Dividend:$1.92
Dividend Yield:3.27%
Dividend Growth:2.20% (3 Year Average)
Payout Ratio:48.24% (Trailing 12 Months of Earnings)
46.15% (Based on This Year's Estimates)
44.14% (Based on Next Year's Estimates)
Track Record:6 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE:MRK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/23/2018quarterly$0.483.52%3/14/20183/15/20184/6/2018
11/28/2017quarterly$0.4812/14/201712/15/20171/8/2018
7/25/2017quarterly$0.479/14/20179/15/201710/6/2017
5/23/2017quarterly$0.472.9%6/13/20176/15/20177/10/2017
2/28/2017quarterly$0.473/13/20173/15/20174/7/2017
11/22/2016quarterly$0.473.05%12/13/201612/15/20161/9/2017
7/26/2016quarterly$0.463.14%9/13/20169/15/201610/7/2016
5/24/2016quarterly$0.463.25%6/13/20166/15/20167/8/2016
2/23/2016quarterly$0.463.64%3/11/20163/15/20164/7/2016
11/24/2015quarterly$0.463.43%12/11/201512/15/20151/8/2016
7/22/2015quarterly$0.453.1%9/11/20159/15/201510/7/2015
5/26/2015quarterly$0.453.03%6/11/20156/15/20157/8/2015
2/24/2015quarterly$0.453.05%3/12/20153/16/20154/8/2015
11/25/2014quarterly$0.453.01%12/11/201412/15/20141/8/2015
7/23/2014quarterly$0.443.02%9/11/20149/15/201410/7/2014
5/27/2014quarterly$0.443.12%6/12/20146/16/20147/8/2014
2/25/2014quarterly$0.443.13%3/13/20143/17/20144/7/2014
11/26/2013quarterly$0.443.53%12/12/201312/16/20131/8/2014
7/24/2013quarterly$0.433.57%9/12/20139/16/201310/7/2013
5/28/2013quarterly$0.433.67%6/13/20136/17/20137/8/2013
2/26/2013quarterly$0.434%3/13/20133/15/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Merck & Co. (NYSE MRK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.32%
Institutional Ownership Percentage: 74.60%
Insider Trading History for Merck & Co. (NYSE:MRK)
Insider Trading History for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE MRK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Weir Mirian M. GraddickInsiderSell24,000$58.00$1,392,000.00View SEC Filing  
2/9/2018Wendell P WeeksDirectorSell5,000$53.57$267,850.005,100View SEC Filing  
1/16/2018Michael J. HolstonEVPSell12,500$61.63$770,375.00View SEC Filing  
1/16/2018Weir Mirian M GraddickInsiderSell60,000$61.63$3,697,800.00101,484View SEC Filing  
1/12/2018Weir Mirian M GraddickInsiderSell5,000$58.00$290,000.00101,484View SEC Filing  
11/8/2017Thomas H GlocerDirectorSell5,000$56.20$281,000.00View SEC Filing  
5/12/2017C Robert KidderDirectorSell5,000$63.54$317,700.0014,317View SEC Filing  
4/3/2017Adam H SchechterEVPSell53,850$63.48$3,418,398.00View SEC Filing  
2/8/2017Patricia F RussoDirectorSell5,000$64.42$322,100.0018,148View SEC Filing  
2/6/2017Wendell P WeeksDirectorSell5,000$64.51$322,550.005,100View SEC Filing  
2/3/2017Michael J HolstonEVPSell91,959$63.96$5,881,697.64105,559View SEC Filing  
2/3/2017Thomas R CechDirectorSell5,000$63.42$317,100.005,100View SEC Filing  
11/10/2016Kenneth C FrazierChairmanSell140,000$65.03$9,104,200.00514,957View SEC Filing  
11/7/2016Julie L GerberdingEVPSell85,523$60.02$5,133,090.4677,762View SEC Filing  
11/2/2016Rochelle B LazarusDirectorSell20,000$59.06$1,181,200.009,594View SEC Filing  
10/3/2016Weir Mirian M GraddickInsiderSell40,800$62.07$2,532,456.00128,973View SEC Filing  
9/1/2016Adam H SchechterEVPSell39,200$62.61$2,454,312.0039,200View SEC Filing  
8/10/2016Clark GolestaniEVPSell3,000$63.03$189,090.00View SEC Filing  
8/5/2016Kenneth C FrazierChairmanSell392,000$61.81$24,229,520.00760,877View SEC Filing  
7/5/2016Kenneth C FrazierCEOSell60,000$58.00$3,480,000.00554,856View SEC Filing  
7/5/2016Weir Mirian M GraddickInsiderSell45,000$57.99$2,609,550.00123,151View SEC Filing  
7/1/2016Adam H SchechterEVPSell50,000$57.69$2,884,500.0050,000View SEC Filing  
7/1/2016Weir Mirian M GraddickInsiderSell30,000$57.49$1,724,700.00162,151View SEC Filing  
5/20/2016Clark GolestaniEVPSell39,877$54.79$2,184,860.8317,083View SEC Filing  
4/14/2016Kenneth C FrazierCEOSell131,040$56.11$7,352,654.40653,517View SEC Filing  
11/4/2015Wendell P. WeeksDirectorSell5,000$55.53$277,650.00100View SEC Filing  
10/29/2015Adele D. AmbroseinsiderSell37,313$55.08$2,055,200.0419,695View SEC Filing  
10/29/2015Kenneth C. FrazierCEOSell18,666$54.69$1,020,843.54438,236View SEC Filing  
10/28/2015Peter C. WendellDirectorSell5,000$54.85$274,250.001,000View SEC Filing  
5/11/2015Adam H SchechterEVPSell10,634$60.44$642,718.96View SEC Filing  
5/8/2015Julie L GerberdingEVPSell38,368$60.99$2,340,064.32View SEC Filing  
5/4/2015Bruce N KuhlikInsiderSell56,064$60.20$3,375,052.80View SEC Filing  
4/29/2015Bruce N KuhlikInsiderSell156,902$59.82$9,385,877.64View SEC Filing  
4/29/2015Michael J HolstonEVPSell95,624$59.84$5,722,140.16View SEC Filing  
2/18/2015Kenneth C FrazierCEOSell5,164$58.67$302,971.88View SEC Filing  
2/11/2015Willie A DeeseInsiderSell135,864$58.56$7,956,195.84View SEC Filing  
2/9/2015Peter C WendellDirectorSell5,000$58.76$293,800.00View SEC Filing  
1/15/2015Adam H SchechterEVPSell74,200$62.48$4,636,016.00View SEC Filing  
1/9/2015Kenneth C FrazierCEOSell8,840$62.47$552,234.80View SEC Filing  
12/10/2014Kenneth C FrazierCEOSell9,846$60.00$590,760.00View SEC Filing  
12/8/2014Bruce N KuhlikInsiderSell50,000$62.00$3,100,000.00View SEC Filing  
11/26/2014Rochelle B LazarusDirectorSell10,000$59.63$596,300.00View SEC Filing  
11/24/2014Wendell P WeeksDirectorSell5,000$59.13$295,650.00View SEC Filing  
11/10/2014Kenneth C FrazierCEOSell10,000$57.98$579,800.00View SEC Filing  
10/10/2014Kenneth C FrazierCEOSell9,895$59.73$591,028.35View SEC Filing  
9/10/2014Kenneth C FrazierCEOSell9,814$60.48$593,550.72View SEC Filing  
8/25/2014Adam H SchechterEVPSell22,000$59.70$1,313,400.00View SEC Filing  
8/11/2014Kenneth C FrazierCEOSell10,058$57.00$573,306.00View SEC Filing  
8/4/2014Adele D AmbroseInsiderSell28,669$56.64$1,623,812.16View SEC Filing  
7/10/2014Kenneth C FrazierCEOSell9,987$58.03$579,545.61View SEC Filing  
7/7/2014Weir Mirian M GraddickInsiderSell180,047$59.16$10,651,580.52View SEC Filing  
6/27/2014Willie A DeeseInsiderSell72,290$58.26$4,211,615.40View SEC Filing  
6/10/2014Kenneth C FrazierCEOSell9,985$58.06$579,729.10View SEC Filing  
5/14/2014Adam SchechterEVPSell10,527$55.91$588,564.57View SEC Filing  
4/10/2014Kenneth FrazierCEOSell10,047$57.24$575,090.28310,494View SEC Filing  
4/4/2014Bruce KuhlikInsiderSell145,225$56.43$8,195,046.75121,845View SEC Filing  
2/14/2014Clark GolestaniEVPSell5,990$55.47$332,265.306,046View SEC Filing  
2/13/2014Bridgette HellerVPSell43,870$55.04$2,414,604.8027,587View SEC Filing  
2/11/2014Adam SchechterEVPSell18,000$55.61$1,000,980.00View SEC Filing  
2/11/2014John CananInsiderSell10,000$55.70$557,000.0010,697View SEC Filing  
2/11/2014Kenneth FrazierCEOSell41,520$54.52$2,263,670.40262,829View SEC Filing  
2/10/2014Peter WendellDirectorSell5,000$54.44$272,200.001,000View SEC Filing  
2/10/2014Willie DeeseInsiderSell50,000$54.68$2,734,000.00106,049View SEC Filing  
8/7/2013Willie DeeseInsiderSell50,638$48.55$2,458,474.90106,040View SEC Filing  
5/15/2013Adele D AmbroseInsiderSell34,208$46.66$1,596,145.28View SEC Filing  
5/13/2013Bridgette P HellerVPSell5,404$46.15$249,394.60View SEC Filing  
8/9/2012Willie A DeeseInsiderSell62,324$44.26$2,758,460.24View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Merck & Co. (NYSE MRK) News Headlines

Source:
DateHeadline
BMO Capital Markets Reaffirms "Sell" Rating for Merck & Co. (MRK)BMO Capital Markets Reaffirms "Sell" Rating for Merck & Co. (MRK)
www.americanbankingnews.com - April 19 at 10:12 PM
Merck & Co. (MRK) Downgraded by BidaskClubMerck & Co. (MRK) Downgraded by BidaskClub
www.americanbankingnews.com - April 19 at 1:22 PM
Form 3 Merck & Co., Inc. For: Apr 16 Filed by: Zachary JenniferForm 3 Merck & Co., Inc. For: Apr 16 Filed by: Zachary Jennifer
www.streetinsider.com - April 19 at 9:51 AM
BRIEF-Merck Says Open Offer For Buying Cos Shares By Procter And Gamble Overseas IndiaBRIEF-Merck Says Open Offer For Buying Co's Shares By Procter And Gamble Overseas India
www.reuters.com - April 19 at 9:51 AM
P&G poised to buy Merck consumer-health unitP&G poised to buy Merck consumer-health unit
www.marketwatch.com - April 19 at 9:51 AM
P&G to Buy German Mercks Consumer Unit for $4.2 BillionP&G to Buy German Merck's Consumer Unit for $4.2 Billion
www.bloomberg.com - April 19 at 9:51 AM
Merck & Co. to Post Q4 2018 Earnings of $1.06 Per Share, SunTrust Banks Forecasts (MRK)Merck & Co. to Post Q4 2018 Earnings of $1.06 Per Share, SunTrust Banks Forecasts (MRK)
www.americanbankingnews.com - April 19 at 7:14 AM
Benzingas Top Analyst Calls From April 18, 2018Benzinga's Top Analyst Calls From April 18, 2018
finance.yahoo.com - April 18 at 4:24 PM
Merck Posts Another Advance In The Lucrative Lung Cancer MarketMerck Posts Another Advance In The Lucrative Lung Cancer Market
seekingalpha.com - April 18 at 9:56 AM
Merck & Co. Expected to Post Q1 2018 Earnings of $1.01 Per Share (MRK)Merck & Co. Expected to Post Q1 2018 Earnings of $1.01 Per Share (MRK)
www.americanbankingnews.com - April 18 at 7:52 AM
Weir Mirian M. Graddick Sells 24,000 Shares of Merck & Co. (MRK) StockWeir Mirian M. Graddick Sells 24,000 Shares of Merck & Co. (MRK) Stock
www.americanbankingnews.com - April 17 at 7:11 PM
One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers RatingsOne Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings
www.msn.com - April 17 at 4:28 PM
Merck (MRK) Shares Cross Above 200 DMAMerck (MRK) Shares Cross Above 200 DMA
www.nasdaq.com - April 17 at 4:28 PM
Why Merck Is Betting Big on One Cancer DrugWhy Merck Is Betting Big on One Cancer Drug
www.wsj.com - April 17 at 4:28 PM
Merck & Co. (MRK) Lifted to "Buy" at Zacks Investment ResearchMerck & Co. (MRK) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 12:47 PM
Merck & Co. (MRK) Given New $70.00 Price Target at Bank of AmericaMerck & Co. (MRK) Given New $70.00 Price Target at Bank of America
www.americanbankingnews.com - April 17 at 11:01 AM
Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease VaccineMerck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine
finance.yahoo.com - April 17 at 9:45 AM
Merck Begins Two Phase 3 Studies Of Pneumococcal Disease Vaccine PCV-15 (V114)Merck Begins Two Phase 3 Studies Of Pneumococcal Disease Vaccine PCV-15 (V114)
www.nasdaq.com - April 17 at 9:45 AM
Merck Wins Big Against Rivals in Lung Cancer Study Survival RatesMerck Wins Big Against Rivals in Lung Cancer Study Survival Rates
www.msn.com - April 17 at 9:45 AM
Expectations from Novartis’s 1Q18 EarningsExpectations from Novartis’s 1Q18 Earnings
finance.yahoo.com - April 17 at 9:45 AM
Merck & Co. (MRK) Raised to "Buy" at Morgan StanleyMerck & Co. (MRK) Raised to "Buy" at Morgan Stanley
www.americanbankingnews.com - April 17 at 8:10 AM
Dow Movers: DIS, MRK - Presented by: The Aol. On NetworkDow Movers: DIS, MRK - Presented by: The Aol. On Network
www.nasdaq.com - April 16 at 4:28 PM
Merck & Co Inc. (MRK) Is Climbing On Study ResultsMerck & Co Inc. (MRK) Is Climbing On Study Results
www.nasdaq.com - April 16 at 4:28 PM
UnitedHealth, Merck Lift the Dow MondayUnitedHealth, Merck Lift the Dow Monday
247wallst.com - April 16 at 4:28 PM
Was Merck & Co Inc.’s (NYSE:MRK) Earnings Decline Part Of A Broader Industry Downturn?Was Merck & Co Inc.’s (NYSE:MRK) Earnings Decline Part Of A Broader Industry Downturn?
finance.yahoo.com - April 16 at 4:28 PM
Merck Notches Key Win Over Bristol-Myers on Lung Cancer Study DataMerck Notches Key Win Over Bristol-Myers on Lung Cancer Study Data
www.thestreet.com - April 16 at 4:28 PM
Mercks Keytruda Reduces Death Risk in Melanoma PatientsMerck's Keytruda Reduces Death Risk in Melanoma Patients
www.zacks.com - April 16 at 9:46 AM
Today’s Research Reports on Trending Tickers: Aphria and Merck & CompanyToday’s Research Reports on Trending Tickers: Aphria and Merck & Company
finance.yahoo.com - April 16 at 9:46 AM
Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 StudyMerck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study
finance.yahoo.com - April 16 at 9:46 AM
Bristol-Myers says cancer drug combo reduces death riskBristol-Myers says cancer drug combo reduces death risk
finance.yahoo.com - April 16 at 9:46 AM
Bristol-Myers Says Lung Cancer Drug Combination Met Trial GoalBristol-Myers Says Lung Cancer Drug Combination Met Trial Goal
finance.yahoo.com - April 16 at 9:46 AM
[$$] New Drug Combinations Improve Survival in Lung Cancer[$$] New Drug Combinations Improve Survival in Lung Cancer
finance.yahoo.com - April 16 at 9:46 AM
Merck & Co. (MRK) Rating Reiterated by BMO Capital MarketsMerck & Co. (MRK) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - April 16 at 7:01 AM
Merck & Co. (MRK) Expected to Post Q1 2018 Earnings of $0.99 Per ShareMerck & Co. (MRK) Expected to Post Q1 2018 Earnings of $0.99 Per Share
www.americanbankingnews.com - April 16 at 1:19 AM
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent Compared to Placebo as Adjuvant Therapy in Resected, High-Risk Stage III MelanomaMerck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent Compared to Placebo as Adjuvant Therapy in Resected, High-Risk Stage III Melanoma
finance.yahoo.com - April 15 at 4:30 PM
Merck & Co. (MRK) Price Target Raised to $72.00Merck & Co. (MRK) Price Target Raised to $72.00
www.americanbankingnews.com - April 15 at 8:37 AM
[$$] Why Merck Is Betting Big on One Cancer Drug[$$] Why Merck Is Betting Big on One Cancer Drug
finance.yahoo.com - April 15 at 8:25 AM
Merck & Co. (MRK) Raised to Hold at BidaskClubMerck & Co. (MRK) Raised to Hold at BidaskClub
www.americanbankingnews.com - April 14 at 5:18 PM
Zacks Investment Research Lowers Merck & Co. (MRK) to HoldZacks Investment Research Lowers Merck & Co. (MRK) to Hold
www.americanbankingnews.com - April 14 at 10:05 AM
Incytes Failure With Mercks Keytruda Has No Implications For OncoSecIncyte's Failure With Merck's Keytruda Has No Implications For OncoSec
seekingalpha.com - April 13 at 4:25 PM
Lung cancer battle brewsLung cancer battle brews
finance.yahoo.com - April 13 at 4:25 PM
Merck & Co. (MRK) Given a $56.00 Price Target by Jefferies Group AnalystsMerck & Co. (MRK) Given a $56.00 Price Target by Jefferies Group Analysts
www.americanbankingnews.com - April 13 at 10:37 AM
Your post-surgery pain is this San Francisco drugmaker's gain and opioid users may benefit, tooYour post-surgery pain is this San Francisco drugmaker's gain and opioid users may benefit, too
finance.yahoo.com - April 12 at 4:25 PM
Merck & Co., Inc. (MRK) Lowered to Sell at BidaskClubMerck & Co., Inc. (MRK) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 11 at 8:59 PM
Merck & Co., Inc. (MRK) Lifted to Hold at Merck & Co., Inc. (MRK) Lifted to Hold at
www.americanbankingnews.com - April 11 at 8:26 PM
Merck & Co., Inc. (MRK) Receives Consensus Recommendation of "Buy" from AnalystsMerck & Co., Inc. (MRK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 11 at 7:35 PM
Novartis’s Valuation and Analysts’ Recommendations on April 11Novartis’s Valuation and Analysts’ Recommendations on April 11
finance.yahoo.com - April 11 at 4:24 PM
A shingles vaccine can improve your health — especially if you’re over 50A shingles vaccine can improve your health — especially if you’re over 50
finance.yahoo.com - April 11 at 4:24 PM
Why Barclays Upgraded Merck to ‘Overweight’ on April 5Why Barclays Upgraded Merck to ‘Overweight’ on April 5
finance.yahoo.com - April 11 at 10:17 AM
3 Reasons to Be Bullish on Merck & Co., Inc. Stock3 Reasons to Be Bullish on Merck & Co., Inc. Stock
investorplace.com - April 10 at 4:22 PM

SEC Filings

Merck & Co. (NYSE:MRK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Merck & Co. (NYSE:MRK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Merck & Co. (NYSE MRK) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.